Introduction
Rheumatoid Arthritis (RA) is a chronic, systemic, inflammatory disorder of unknown aetiology that primarily involves joints. In the United Kingdom, the overall minimum prevalence of RA is 1.16% in women and 0.44% in men. 1 Recent, mounting evidence, associates RA with excessive cardiovascular morbidity and mortality including acute coronary syndromes (ACS), heart failure and coronary death. 2, 3 The causes for this are likely to be several and include a high prevalence of classical and non-traditional cardiovascular (CV) risk factors. [4] [5] [6] [7] Hypertension (HT), the most important classical risk factor for ACS and stroke, 8 is particularly prevalent in RA. 4, 9, 10 Uric acid is an ubiquitous byproduct of purine metabolism and was thought to have a beneficial role by acting as an antioxidant. 11 Serum uric acid (SUA) levels are frequently high in hypertensive patients. A quarter of untreated hypertensives, 50% of patients on diuretics and 475% of subjects with malignant HT or renal dysfunction have raised SUA. 12 SUA has been pathogenically linked to cardiovascular disease (CVD) and HT. Even when adjusted for traditional CV risk factors, age, race and use of diuretics, SUA is an independent, significant factor for the development of CVD in general, 13 and possibly in the RA population 6 and predicts approximately a twofold increase in the frequency of HT in the general population after 5-10 years. 14 Interestingly, the simultaneous occurrence of RA and gout is infrequent even though both are widespread rheumatological conditions, 15 thus suggesting a potential repressing influence of raised SUA levels on rheumatoid inflammation.
Aging and obesity 16 are known predictors of HT in the general population, smoking 17 and smoking cessation 18 may also contribute. Non-steroidal antiinflammatory drugs (NSAID), COX-2 inhibitors (Coxibs), low-dose (75 mg) aspirin and medium dose (X7.5 mg) oral steroids are all commonly used in RA and, together with some disease-modifying antirheumatic drugs (DMARDs), such as cyclosporine and leflunomide, may cause HT. 19, 20 Finally, HT associates with, or even forms part of, common co-morbidities in RA, such as insulin resistance and the metabolic syndrome. 21 In this cross-sectional study, we evaluated whether SUA levels are raised in hypertensive RA patients and whether they associate independently with hypertensive status in this disease.
Materials and methods
A total of 400 consecutive consenting RA patients, meeting 1987 revised ACR criteria, 22 were recruited from routine outpatient clinics at the Department of Rheumatology of the Dudley Group of Hospitals, United Kingdom, between 1 August 2004 and 31 July 2006. The study had local Research Ethics Committee approval.
Patient assessment included full medical history, detailed recording of all medication with exact indication (including use of NSAIDs, Coxibs and medium dose (X7.5 mg) oral prednisolone), contemporary assessments of height, weight, body mass index (BMI), disease duration, rheumatoid factor (RF) positivity, current disease activity score (DAS28) 23 and physical function using the Health Assessment Questionnaire (HAQ). 24 Blood pressure (BP) was the mean of three measurements taken from the right arm with an appropriately sized cuff using a Criticare 506DXN machine, Systems Inc. with the patient seated. The presence of HT was defined as systolic BPX140 mm Hg and/or diastolic BPX90 mm Hg and/or the use of antihypertensive medications according to the British Hypertension Society/NICE guidelines. Patients were defined diabetic when fasting serum glucose levels were 47 mmol l À1 and/or oral hypoglycaemic medications or insulin were used. Number of packyears of smoking was recorded and patients were categorized as current smokers, ex smokers, never smoked.
All biochemical tests were carried out in the Biochemistry Laboratory of Russells Hall hospital, Dudley Group of hospitals NHS Trust, United Kingdom. Blood samples were drawn after a 12-h fast for routine biochemistry in Z Serumsep, Clot Activator Vacuette tubes, greiner bio-one. Samples were spun at 4500 g for 5 min and the serum pipetted out for further testing. Routine tests were carried out on the same day and serum for insulin was frozen at À40 1C until assay. Uric acid, total cholesterol, high-density lipoproteins (HDL) cholesterol, triglycerides and glucose were measured using the Vitros 5, 1 FS chemistry system (www.orthoclinical.com). SUA is reported in mg dl À1 ; this can be converted to mmol l À1 if multiplied by 59.48. Renal function was assessed by estimated glomerular filtration rate using the six-variable Modification of Diet in Renal Disease (MDRD) equation. 25 Insulin resistance was evaluated from fasting glucose and insulin using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). 26 
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate whether each parameter followed a Gaussian distribution. Values are expressed as mean7standard deviation (s.d.) or percentages, as appropriate. Binary logistic regression analysis was utilized to evaluate the independence of the association of SUA with HT when adjusting for HT risk factors and associations (age, sex, smoking status, BMI, HDL, triglycerides (TG), HOMA-IR, full MDRD) RA characteristics (disease duration, HAQ, DAS28) and use of medication with known BP raising properties (NSAID or Coxib, medium dose prednisolone, cyclosporine, leflunomide and aspirin). Significance was set at Po0.05. Analyses were carried out using SPSS 13.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Participants were mainly Caucasian British (96%) females (73%) with a mean age of 62712 years and mean SUA levels 5.271.5 mg dl À1 (309.37 89.22 mmol l À1 ) (range 2.1-13.1 mg dl À1 (124.91-779.19 mmol l À1 ). A total of 282 (70.5%) patients were hypertensive, from which 171 (60.6%) were on antihypertensive treatment and 11 (39.4%) had untreated HT. The median (interquartile range) disease duration in our population was 10 (4-18), the median (interquartile range) HAQ score was 1.5 (0.63-2.13) and the mean7s.d. DAS28 score was 4.2171.4. No significant differences were observed in the above RA characteristics between hypertensive and normotensive RA patients. A total of 296 (75.7%) patients were RF positive, 350 (87.5%) on DMARDs (the majority (56.3%) on methotrexate) and 71 (17.9%) on medium dose oral daily prednisolone. A total of 37 (9.3%) patients (6 men and 31 women) were hyperuricaemic as defined by UA levels 48.4 mg dl À1 (500 mmol l À1 ) for males and 46.7 mg dl À1 (400 mmol l À1 ) for females.
Patients with HT had significantly higher SUA levels compared to normotensives (5.4471.6 mg dl À1 (323.57795.17 mmol l À1 ) vs 4.5671.1 mg dl À1 (271.237 65.43 mmol l À1 ), Po0.001). There was a 1.6-fold increase in the crude odds of being hypertensive, per each mg dl À1 (or 59.48 mmol l À1 ) increase in SUA levels (OR ¼ 1.59, CI: 1.34-1.9; Po0.001) ( Figure 1 ). This remained virtually unchanged (OR ¼ 1.59, 95% CI: 1.21-2.1; P ¼ 0.001) after adjustment for all known risk factors for HT assessed in this study, including age, sex, BMI, smoking status (never smoked, ex smoker, current smoker), metabolic abnormalities such as dyslipidaemia (HDL, TG) and insulin resistance (HOMA-IR), renal function (full MDRD), RA characteristics (DAS28, HAQ, Disease Duration) and drugs (NSAIDs, Coxibs, steroids, cyclosporine, leflunomide, aspirin). The association was also significant in patients who did not use diuretics (OR ¼ 1.5, 95% CI: 1.1-2.05; P ¼ 0.011) ( Table 1 ).
Discussion
This study suggests that raised SUA levels associate independently with HT in RA patients, implying a direct link that cannot be explained via other HT risk factors (age, sex, obesity, dyslipidaemia), RA characteristics (disease duration, DAS28, HAQ), medications (including NSAIDs, Coxibs, steroids, leflunomide, cyclosporine, diuretics and low-dose aspirin) or relevant co-morbidities (insulin resistance or renal dysfunction). Though large, this study is cross-sectional, so it cannot prove causality and any interpretation of the results should be made with caution. It can however serve for hypothesisgeneration and inform future prospective clinical and mechanistic studies.
The prevalence of HT per 1 mg dl À1 (59.48 mmol l À1 ) SUA increase in this RA cohort forms a J-shaped curve. Almost all studies examining the relation of SUA and CVD in the general population also show a J-shaped curve. 11 It is possible that this reflects a continuum, from decreased plasma antioxidant activity (at very low-SUA levels) to normality and then increasing detrimental vascular effects counteracting antioxidant properties, as SUA levels increase. It would be interesting to know how this curve would compare to a non-RA population and the absence of a control group is one of the weaknesses of the present study.
SUA was first noted to be associated with increased BP by Frederick Mohamed in the 1870s and several studies have confirmed this relationship in the general population. 27, 28 New onset essential HT in adolescents is associated with elevated SUA in the vast majority of cases. In contrast, raised SUA is present only in 30% of subjects with secondary HT and is rare in white-coat and normotensive adolescents. Furthermore, in a recent study Coutinho et al. 29 concluded that in hypertensive individuals, SUA levels are inversely associated with resting forearm blood flow and reactive hyperaemia, both markers of microvascular function. Therefore, providing evidence of a link between raised SUA and endothelial dysfunction in hypertensive patients that could imply nocturnal BP non-dipping and thus increased risk for CVD. 30 There are many mechanisms by which HT may lead to, or co-exist with, raised SUA in the same patient. 11 HT leads to renal damage and reduced renal blood flow, thus promoting absorption of both UA and sodium. HT can also cause renal microvascular disease, local ischaemia and subsequent SUA elevation. Lactate products block urate secretion in the proximal tubule and increased levels of xanthine and xanthine oxidase are generated by formation. Furthermore HT frequently coexists with other features of the metabolic syndrome, such as obesity and insulin resistance. The hyperinsulinaemia associated with the latter may stimulate sodium and UA absorption from the proximal tubule. 31 However, several studies suggest that SUA may be directly linked with HT. Analysis of a cohort of male workers in southern Italy 32 showed a positive association between UA and the development of HT independent of age, BMI and lipids; similar results (controlled for body-weight, serum creatinine, alcohol consumption, parental history of HT, excessive salt intake and truncal fat) were also reported in a cohort of the Kaiser Permanente Medical Care Programme. 33 Notwithstanding the limitations of the cross-sectional design of our study, this also appears to suggest that SUA may be directly linked to HT in patients with RA. It is accepted that there is a negative association between gout and RA. 34 Two decades ago Turner et al. 35 demonstrated in an in vitro system that high levels of uric acid inhibit the production of RF and could therefore have immunosuppressive properties. Other mechanisms proposed to explain the mutual exclusion between gout and RA include impaired phagocytic function of neutrophils in rheumatoid joint fluid 36 and inhibition of the activation of cellular and serological inflammatory mediators by coating of monosodium urate crystals by RF. 37 In a clinical study, Agudelo et al. 38 suggest that persistent hyperuricaemia may protect against or decrease the expression of rheumatoid inflammation. In this context, someone would expect higher SUA levels to have anti-inflammatory properties. Given the established association between HT and inflammation, 39 the latter would suggest that any correlation between SUA levels and HT prevalence in RA would be negative. However, the results of the present study suggest that higher SUA levels associate with increased prevalence of HT in RA, as they do in the general population. This association was independent of systemic inflammation, disease duration (which may reflect prolonged NSAID use), the use of RA drugs with possible hypertensive effects, or drugs that alter SUA levels such as diuretics and low-dose aspirin. The latter may be a significant confounder, since the antiplatelet dose of aspirin (75 mg) which is commonly given for primary and secondary CVD prevention in elderly RA patients can lead to significant increments of SUA levels. 40, 41 There are many mechanisms by which UA may cause HT. 11 UA contributes to endothelial dysfunction and impairment of endothelial nitric oxide (NO) release. SUA and serum NO levels vary during the day in a reciprocal pattern, suggesting a pattern of physiological regulation. Increased SUA levels reduce NO levels and activate the renin-angiotensin system thus inducing renal vasoconstriction and subsequent fluid retention. This HT is salt-resistant and it occurs even at a low-salt diet. However, as the condition progresses, renal microvascular disease ensues, leading to sufficient narrowing of the arteriolar lumen and thus to a salt-driven, UAindependent, HT. 42 According to this theory, one would expect higher uric acid levels to be a risk factor for future development of HT. Indeed, Sundstrom et al. 28 using data from the Framingham study demonstrated that serum SUA was an independent predictor of the incidence of HT in the general population. The pathogenesis of this microvascular disease is thought to be due to the combination of persistently raised BP and the direct effects of urate on the vasculature. Experiments on rats treated with oxonic acid (an inhibitor of uricase, a hepatic enzyme that degrades uric acid to allantoin) 43 have shown a direct correlation of systolic BP and SUA levels, with each 1 mg dl À1 change in UA associated with a 30-40 mm Hg increase in BP. Urate can enter into the vascular smooth cell where it can cause proliferation, activate the local renin-angiotensin system and stimulate the production of various inflammatory mediators including C-reactive protein and monocyte chemoattractant protein-1. SUA also stimulates human mononuclear cells to produce interleukin-1b, interleukin-6 and tumour necrosis factor-a, 11 which can have further downstream functional effects on the vascular endothelium. 44 SUA is not currently considered a risk factor for CVD and asymptomatic hyperuricaemia is considered benign and not requiring treatment. 45 This may change in the near future if allopurinol (a xanthine oxidase inhibitor that can block both UA and oxidant formation) proves to be a useful BP-lowering agent in patients with raised SUA levels at the early stages of HT. Allopurinol or benziodarone (a uricosuric agent) administration to oxonic acidtreated rats prevented both hyperuricaemia and BP elevations, supporting this hypothesis. A pilot study in humans also suggests that lowering UA with allopurinol may lower BP in new onset essential HT in adolescents. 46 Allopurinol, can reverse the impaired endothelial NO production in both heart failure and type 2 diabetes. 47, 48 Although allopurinol leads to significant UA reductions most investigators believe that its beneficial effect may be by reducing oxidative stress. It is possible that treating hyperuricaemia may be effective in lowering BP when hyperuricaemia has not been present for a long time (such as in children with HT and in patients given short-term treatment with cyclosporine or diuretics) or when subjects are given a lowsalt diet which would remove the renal injury. This is the first study to suggest that uric acid levels may be implicated in the pathogenesis of HT in patients with RA. Interestingly, this association is independent of the underlying systemic inflammation and drugs commonly used by these patients. These findings must be confirmed in longitudinal cohorts and specific mechanisms could be addressed in studies designed specifically for the purpose.
